Escherichia coli Microcin B17 as a chassis for the development of novel antimicrobial peptides.
Withanage, S.; Masschelein, J.; Pinheiro, V. B.
Show abstract
Antimicrobial resistance remains an urgent and growing global health problem. Peptides with antimicrobial activity are widespread in nature but are rarely harnessed for application, making them an underexplored and untapped resource. Many harbor post-translational modifications, which are essential for function and have evolved alongside specialized export and immunity machineries - leading to the current paradigm that natural sequences cannot be changed, and curtailing their development as antimicrobial agents. Nonetheless, we found sufficient ambiguity in literature to question if that remained true for E. coli MccB17. We demonstrate that its natural machinery for synthesis, export and immunity, can be co-opted as a platform for novel azole-modified antimicrobial peptide discovery. We show that the sequence space available for exploration is large and densely populated with functional sequences. One-Sentence SummaryE. coli can be harnessed as an in vivo platform for the isolation of novel antimicrobial azole-modified peptides.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Metabolic pathway rerouting in Paraburkholderia rhizoxinica evolved long-overlooked derivatives of coenzyme F420 93%
- Docking Domain Engineering in a Modular Polyketide Synthase and its Impact on Structure and Function 93%
- Biosynthesis of cittilins, unusual ribosomally synthesized and post-translationally modified peptides from Myxococcus xanthus 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.